Schizophrenia Clinical Trials in New York

Showing 41-60 of 81 trials

Can Cognitive Training Decrease Reactive Aggression?

NCT03623477

The purpose of the study is to examine the effects of cognitive training on emotion regulation, impulse control, and aggression in people with schizophrenia. The study compares a combination of computerized cognitive remediation and social cognition training (CRT+SCT) to cognitive remediation alone (CRT). Study outcomes include multiple measures of aggression, emotion regulation, impulse control, cognition, and symptoms.

SchizophreniaCognitive DeficitsImpulsive Aggression+2 more

Weill Medical College of Cornell University90 participantsStarted Aug 2016

New York, New York, United States • White Plains, New York, United States

COMPLETEDPHASE3< 1 mile

Pediatric Open-Label Extension Study

NCT01914393

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

SchizophreniaAutismBipolar Depression

Sumitomo Pharma America, Inc.702 participantsStarted Sep 2013

Dothan, Alabama, United States • Downey, California, United States • San Francisco, California, United States +85 more locations

Can Cognitive Training Decrease Reactive Aggression?

Pediatric Open-Label Extension Study

Schizophrenia Trials in Other Cities

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Trial of Treatment for Internalized Stigma in Schizophrenia

Metformin for Weight Loss in Schizophrenia

Neuropsychological Evaluation of Psychiatric and Neurological Patients

A Multicenter Study of NAP (AL-108) in Schizophrenia

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

Safety and Efficacy of Cariprazine in Schizophrenia

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Improving Care and Reducing Cost Study

An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia

Other Conditions in New York